<DOC>
	<DOCNO>NCT02746796</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety ONO-4538 chemotherapy unresectable advanced recurrent gastric cancer ( include esophagogastric junction cancer ) previously treat first-line therapy . Part 1 intended evaluate tolerability , safety , efficacy ONO-4538 combination SOX therapy ( Tegafur / gimeracil / oteracil potassium + Oxaliplatin ) CapeOX therapy ( Capecitabine + Oxaliplatin ) . In part 2 , investigator subinvestigator choose chemotherapy ( SOX CapeOX therapy ) , take account condition subject . Part 2 plan evaluate efficacy safety ONO-4538 + chemotherapy comparison placebo + chemotherapy .</brief_summary>
	<brief_title>Study ONO-4538 Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients unresectable advanced recurrent gastric cancer ( include esophagogastric junction cancer ) treat firstline therapy systemic antitumor agent advance recurrent gastric cancer ( include esophagogastric junction cancer ) Have measurable lesion define RECIST Guideline Version 1.1 ECOG PS score 0 1 Have life expectancy least 3 month Have multiple cancer Have current past history severe hypersensitivity antibody product Patients metastasis brain meninx symptomatic require treatment Patients active , know suspected autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>